PI3K

illustration of venture capital investment funding

Incyte vets raise $102M to create better PARP, PI3K drugs

A group of familiar faces to Incyte watchers has broken off to create competitors to approved cancer drugs from AstraZeneca, GSK, Novartis and Pfizer.

Nick Paul Taylor Jan 24, 2024 8:38am

Adlai bags $57.5M IPO to test ex-Novartis cancer drug in phase 3

Sep 29, 2023 10:00am

2 more biotechs report pipeline, partnership changes

May 12, 2023 11:15am

Incyte scraps six R&D programs

May 2, 2023 12:48pm

FDA feedback drives MEI, Kyowa to halt blood cancer program

Dec 6, 2022 7:18am

A stock ticker showing financial information

MEI, Kyowa confirm phase 2 cancer efficacy with fresh data drop

Nov 18, 2022 9:35am